Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer (mRCC) patients (pts)
| العنوان: | Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer (mRCC) patients (pts) |
|---|---|
| المؤلفون: | Mariette Labots, Mohammad O. Hoque, Henk M.W. Verheul, Shahnaz Begum, Mohammad E. Allaf, George J. Netto, Gerrit A. Meijer, Jenny J. Kim, Luigi Marchionni, Michael A. Carducci, Hans J. Hammers |
| المصدر: | Journal of Clinical Oncology. 31:4566-4566 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Oncology, Epigenetic biomarkers, Cancer Research, medicine.medical_specialty, Sunitinib, business.industry, Bioinformatics, Genome, Biomarker (cell), Methylation profiling, Internal medicine, medicine, Metastatic renal cell cancer, business, medicine.drug |
| الوصف: | 4566 Background: There exists a significant heterogeneity in the clinical response to sunitinib among pts treated for mRCC and, thus, a biomarker which would predict pts’ response up front would be an invaluable tool in the clinical management of these pts. In this regard, whole genome methylation array was performed between 2 extreme groups: sunitinib responders (RES) and non-responders (NRES) to identify differentially methylated genes between these subsets of pts. Methods: mRCC pts who received sunitinib therapy with available frozen nephrectomy tissues (stored at -80°C) and clinical data were identified. RES were identified as pts with progression free survival (PFS) of > or =11 months (mos) and NRES as those with PFS < or = 3 mos. After DNA extraction and quality assurance according to standard protocol, whole genome methylation array was performed using Infinium Humanmethylation450 BeadChip Kit - Illumina. Data normalization was achieved by subset-quantile within array normalization (PMID: 22703947). Differentially methylated regions were identified using logit transformed Beta values, using an F-test after shrinking variance via empirical Bayes (PMID: 21118553). Results: Total of 13 pts who received sunitinib therapy with available frozen nephrectomy tissues were identified. Of the 13, 5 pts qualified for each RES and NRES cohort as described in methods section. All pts in RES group had clear cell subtype. Two pts of the NRES group were of non-clear cell subtype. The QC plots showed that all arrays were successful. For RES vs. NRES, one genomic location, DENND2D, was significantly hypermethylated in the RES group with a false discovery rate (FDR) of |
| تدمد: | 1527-7755 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::44b7fe17c7e075d3949139cb993b740dTest https://doi.org/10.1200/jco.2013.31.15_suppl.4566Test |
| رقم الانضمام: | edsair.doi...........44b7fe17c7e075d3949139cb993b740d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|